Hanmi Science Net Assets
Hanmi Science net assets. Based on the latest financial reports, Hanmi Science (008930) has net assets worth ₩1.00 Trillion KRW (≈ $677.74 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.49 Trillion ≈ $1.01 Billion USD) and total liabilities (₩494.84 Billion ≈ $335.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 008930 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩1.00 Trillion |
| % of Total Assets | 66.9% |
| Annual Growth Rate | 9.88% |
| 5-Year Change | 38.95% |
| 10-Year Change | 48.12% |
| Growth Volatility | 16.11 |
Net Assets of Hanmi Science (2000–2025)
Net assets of Hanmi Science from 2000 to 2025. This chart illustrates how Hanmi Science's net assets have evolved over time, based on quarterly financial data. See Hanmi Science (008930) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Hanmi Science (2000–2025)
The table below shows the annual net assets of Hanmi Science from 2000 to 2025. For live market cap and overall valuation, see 008930 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩959.19 Billion ≈ $650.03 Million |
+14.37% |
| 2024-12-31 | ₩838.70 Billion ≈ $568.38 Million |
+6.51% |
| 2023-12-31 | ₩787.47 Billion ≈ $533.66 Million |
+8.65% |
| 2022-12-31 | ₩724.75 Billion ≈ $491.15 Million |
+4.99% |
| 2021-12-31 | ₩690.29 Billion ≈ $467.80 Million |
+4.79% |
| 2020-12-31 | ₩658.73 Billion ≈ $446.41 Million |
+2.02% |
| 2019-12-31 | ₩645.69 Billion ≈ $437.57 Million |
-1.13% |
| 2018-12-31 | ₩653.09 Billion ≈ $442.59 Million |
-1.81% |
| 2017-12-31 | ₩665.15 Billion ≈ $450.76 Million |
+2.72% |
| 2016-12-31 | ₩647.56 Billion ≈ $438.84 Million |
+10.84% |
| 2015-12-31 | ₩584.25 Billion ≈ $395.94 Million |
+39.87% |
| 2014-12-31 | ₩417.71 Billion ≈ $283.08 Million |
+2.11% |
| 2013-12-31 | ₩409.07 Billion ≈ $277.22 Million |
+3.85% |
| 2012-12-31 | ₩393.89 Billion ≈ $266.94 Million |
+5.81% |
| 2011-12-31 | ₩372.25 Billion ≈ $252.27 Million |
-38.45% |
| 2010-12-31 | ₩604.83 Billion ≈ $409.88 Million |
+35.95% |
| 2009-12-31 | ₩444.88 Billion ≈ $301.49 Million |
+13.20% |
| 2008-12-31 | ₩393.00 Billion ≈ $266.33 Million |
+12.02% |
| 2007-12-31 | ₩350.82 Billion ≈ $237.74 Million |
+20.49% |
| 2006-12-31 | ₩291.16 Billion ≈ $197.32 Million |
+32.55% |
| 2005-12-31 | ₩219.66 Billion ≈ $148.86 Million |
+20.82% |
| 2004-12-31 | ₩181.81 Billion ≈ $123.21 Million |
+16.83% |
| 2003-12-31 | ₩155.62 Billion ≈ $105.46 Million |
+6.27% |
| 2002-12-31 | ₩146.43 Billion ≈ $99.23 Million |
+11.19% |
| 2001-12-31 | ₩131.69 Billion ≈ $89.25 Million |
+44.82% |
| 2000-12-31 | ₩90.93 Billion ≈ $61.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hanmi Science's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 98751.6% over the analyzed period, indicating profitable operations and earnings retention.
Hanmi Science Net Assets Breakdown (December 2025)
Hanmi Science net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩757.96 Billion | 78.80% |
| Other Components | ₩203.89 Billion | 21.20% |
| Total Equity | ₩961.85 Billion | 100.00% |
Hanmi Science Competitors by Market Cap
The table below lists competitors of Hanmi Science ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anywhere Real Estate Inc
NYSE:HOUS
|
$1.98 Billion |
|
Anhui Jingcheng Copper Share Co Ltd
SHE:002171
|
$1.98 Billion |
|
IBF Financial Holdings Co Ltd
TW:2889
|
$1.98 Billion |
|
Alliance Financial Group Bhd
KLSE:2488
|
$1.98 Billion |
|
Sh Belling
SHG:600171
|
$1.98 Billion |
|
XiAn Shaangu Power Co Ltd
SHG:601369
|
$1.98 Billion |
|
Central China Land Media Co Ltd
SHE:000719
|
$1.98 Billion |
|
Jiangsu Shemar Electric Co Ltd
SHG:603530
|
$1.98 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hanmi Science's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 840,928,986,270 to 961,852,859,660, a change of 120,923,873,390 (14.4%).
- Net income of 118,369,957,150 contributed positively to equity growth.
- Dividend payments of 13,542,741,200 reduced retained earnings.
- Other factors increased equity by 16,096,657,440.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩118.37 Billion | +12.31% |
| Dividends Paid | ₩13.54 Billion | -1.41% |
| Other Changes | ₩16.10 Billion | +1.67% |
| Total Change | ₩- | 14.38% |
Book Value vs Market Value Analysis
This analysis compares Hanmi Science's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.03x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.19x to 3.03x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩10280.35 | ₩43100.00 | x |
| 2018-12-31 | ₩10095.47 | ₩43100.00 | x |
| 2019-12-31 | ₩9982.34 | ₩43100.00 | x |
| 2020-12-31 | ₩10185.62 | ₩43100.00 | x |
| 2021-12-31 | ₩10261.19 | ₩43100.00 | x |
| 2022-12-31 | ₩10871.82 | ₩43100.00 | x |
| 2023-12-31 | ₩11583.95 | ₩43100.00 | x |
| 2024-12-31 | ₩12418.89 | ₩43100.00 | x |
| 2025-12-31 | ₩14204.70 | ₩43100.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hanmi Science utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.31%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.72%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 1.55x
- Recent ROE (12.31%) is above the historical average (11.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 12.09% | 7.10% | 0.61x | 2.81x | ₩1.84 Billion |
| 2001 | 17.44% | 10.75% | 0.66x | 2.45x | ₩9.00 Billion |
| 2002 | 15.98% | 8.46% | 0.83x | 2.29x | ₩7.99 Billion |
| 2003 | 8.40% | 4.43% | 0.81x | 2.34x | ₩-2.24 Billion |
| 2004 | 18.23% | 8.70% | 0.94x | 2.22x | ₩13.54 Billion |
| 2005 | 20.22% | 10.57% | 0.97x | 1.98x | ₩21.15 Billion |
| 2006 | 26.43% | 16.33% | 0.85x | 1.91x | ₩45.13 Billion |
| 2007 | 16.01% | 9.97% | 0.77x | 2.08x | ₩19.89 Billion |
| 2008 | 19.53% | 11.79% | 0.72x | 2.29x | ₩34.92 Billion |
| 2009 | 12.10% | 7.32% | 0.77x | 2.14x | ₩8.77 Billion |
| 2010 | 1.54% | 0.92% | 0.63x | 2.66x | ₩-32.71 Billion |
| 2012 | 3.18% | 61.85% | 0.04x | 1.24x | ₩-26.79 Billion |
| 2013 | 2.35% | 4.35% | 0.38x | 1.42x | ₩-31.21 Billion |
| 2014 | 5.12% | 4.00% | 0.72x | 1.79x | ₩-20.29 Billion |
| 2015 | 30.59% | 22.99% | 0.83x | 1.60x | ₩120.15 Billion |
| 2016 | 1.23% | 1.19% | 0.69x | 1.50x | ₩-56.59 Billion |
| 2017 | 4.52% | 4.61% | 0.69x | 1.41x | ₩-36.45 Billion |
| 2018 | 2.76% | 2.55% | 0.77x | 1.40x | ₩-47.29 Billion |
| 2019 | 4.76% | 3.76% | 0.90x | 1.41x | ₩-33.83 Billion |
| 2020 | 3.43% | 2.64% | 0.93x | 1.40x | ₩-43.27 Billion |
| 2021 | 6.22% | 4.52% | 1.00x | 1.38x | ₩-26.09 Billion |
| 2022 | 9.55% | 6.62% | 0.94x | 1.53x | ₩-3.27 Billion |
| 2023 | 14.62% | 9.23% | 1.02x | 1.56x | ₩36.37 Billion |
| 2024 | 7.07% | 4.63% | 0.95x | 1.60x | ₩-24.67 Billion |
| 2025 | 12.31% | 8.72% | 0.91x | 1.55x | ₩22.18 Billion |
Industry Comparison
This section compares Hanmi Science's net assets metrics with peer companies in the Medical Distribution industry.
No peer company data available for comparison.
About Hanmi Science
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition… Read more